⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4995276 | 1.00 | — | — | |
| SCHEMBL12205278 | 1.00 | — | — | |
| SCHEMBL20780930 | 1.00 | — | — | |
| SCHEMBL2559930 | 0.79 | — | — | |
| SCHEMBL28530476 | 0.74 | — | — | |
| SCHEMBL771974 | 0.73 | — | — | |
| Isopropyl Alcohol SCHEMBL9131852 | 0.73 | ALDH1A1 (0.38) | — | |
| SCHEMBL703096 | 0.73 | — | — | |
| SCHEMBL5417916 | 0.73 | — | — | |
| SCHEMBL19672403 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3681504-B1 | METHODS OF DETECTION USING X-RAY FLUORESCENCE | ICAGEN INC (US) | 2023-08-23 | — | — | EP | disclosed |
| US-11573224-B2 | Methods of detection using X-ray fluorescence | ICAGEN, LLC (US) | 2023-02-07 | — | — | US | disclosed |
| US-11174273-B2 | Quinazoline analogs as receptor tyrosine kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2021-11-16 | — | — | US | disclosed |
| US-20210284656-A9 | QUINAZOLINE ANALOGS AS RECEPTOR TYROSINE KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2021-09-16 | — | — | US | disclosed |
| US-20210254056-A1 | IDENTIFICATION AND TARGETED MODULATION OF GENE SIGNALING NETWORKS | CAMP4 THERAPEUTICS CORPORATION | 2021-08-19 | — | — | US | disclosed |
| US-10877035-B2 | Advanced drug development and manufacturing | ICAGEN, LLC (US) | 2020-12-29 | — | — | US | disclosed |
| US-20200278346-A1 | METHODS OF DETECTION USING X-RAY FLUORESCENCE | ADJACENT ACQUISITION CO., LLC | 2020-09-03 | — | — | US | disclosed |
| EP-3681504-A1 | METHODS OF DETECTION USING X-RAY FLUORESCENCE | Icagen, Inc. (US) | 2020-07-22 | — | — | EP | disclosed |
| US-20190161500-A1 | QUINAZOLINE ANALOGS AS RECEPTOR TYROSINE KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2019-05-30 | — | — | US | disclosed |
| WO-2019055754-A1 | METHODS OF DETECTION USING X-RAY FLUORESCENCE | ICAGEN, INC. (US) | 2019-03-21 | — | — | WO | disclosed |
| EP-2377539-A1 | Quinazoline analogs as receptor tyrosine kinase inhibitors | Array Biopharma, Inc. (US) | 2011-10-19 | — | — | EP | disclosed |
| EP-2084519-A2 | ADVANCED DRUG DEVELOPMENT AND MANUFACTURING | Los Alamos National Security, LLC (US) | 2009-08-05 | — | — | EP | disclosed |
| US-20090048279-A1 | QUINAZOLINE ANALOGS AS RECEPTOR TYROSINE KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2009-02-19 | — | — | US | disclosed |
| EP-1660090-A4 | QUINAZOLINE ANALOGS AS RECEPTOR TYROSINE KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2008-12-03 | — | — | EP | disclosed |
| US-7452895-B2 | Quinazoline analogs as receptor tyrosine kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2008-11-18 | — | — | US | disclosed |
| WO-2008127291-A2 | ADVANCED DRUG DEVELOPMENT AND MANUFACTURING | LOS ALAMOS NATIONAL SECURITY, LLC (US) | 2008-10-23 | — | — | WO | disclosed |
| US-20080220441-A1 | Advanced drug development and manufacturing | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2008-09-11 | — | — | US | disclosed |
| EP-1660090-A1 | QUINAZOLINE ANALOGS AS RECEPTOR TYROSINE KINASE INHIBITORS | Array Biopharma, Inc. (US) | 2006-05-31 | — | — | EP | disclosed |
| US-20050043334-A1 | Quinazoline analogs as receptor tyrosine kinase inhibitors | ARRAY BIOPHARMA INC. | 2005-02-24 | — | — | US | disclosed |
| WO-2005016346-A1 | QUINAZOLINE ANALOGS AS RECEPTOR TYROSINE KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2005-02-24 | — | — | WO | disclosed |